Skip Navigation

Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination with Axitinib versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients with Metastatic Renal Cell Carcinoma

Brief Summary

Type:
Kidney

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03092856

Study #:
STUDY00143241

Start Date:
Oct 28, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03092856

View Complete Trial Details & Eligibility at ClinicalTrials.gov